- Home
- HIX vs CAPR Comparison
HIX vs CAPR Comparison
Compare HIX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIX
- CAPR
- Stock Information
- Founded
- HIX 1998
- CAPR 2005
- Country
- HIX United States
- CAPR United States
- Employees
- HIX N/A
- CAPR N/A
- Industry
- HIX Finance/Investors Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIX Finance
- CAPR Health Care
- Exchange
- HIX Nasdaq
- CAPR Nasdaq
- Market Cap
- HIX 382.6M
- CAPR 453.9M
- IPO Year
- HIX N/A
- CAPR N/A
- Fundamental
- Price
- HIX $4.29
- CAPR $7.64
- Analyst Decision
- HIX
- CAPR Strong Buy
- Analyst Count
- HIX 0
- CAPR 8
- Target Price
- HIX N/A
- CAPR $27.13
- AVG Volume (30 Days)
- HIX 449.5K
- CAPR 3.9M
- Earning Date
- HIX 01-01-0001
- CAPR 08-06-2025
- Dividend Yield
- HIX 13.14%
- CAPR N/A
- EPS Growth
- HIX N/A
- CAPR N/A
- EPS
- HIX N/A
- CAPR N/A
- Revenue
- HIX N/A
- CAPR $17,363,588.00
- Revenue This Year
- HIX N/A
- CAPR $453.92
- Revenue Next Year
- HIX N/A
- CAPR N/A
- P/E Ratio
- HIX N/A
- CAPR N/A
- Revenue Growth
- HIX N/A
- CAPR N/A
- 52 Week Low
- HIX $4.16
- CAPR $3.52
- 52 Week High
- HIX $5.08
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- HIX 61.64
- CAPR 38.00
- Support Level
- HIX $4.28
- CAPR $9.65
- Resistance Level
- HIX $4.26
- CAPR $11.88
- Average True Range (ATR)
- HIX 0.03
- CAPR 1.05
- MACD
- HIX -0.00
- CAPR -0.11
- Stochastic Oscillator
- HIX 82.35
- CAPR 17.51
About HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.